相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma
Paolo Strati et al.
HAEMATOLOGICA (2021)
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia
Yair Herishanu et al.
BLOOD (2021)
Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution
Fulvia Pimpinelli et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study
Jingxin Li et al.
NATURE MEDICINE (2021)
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies
Francesco Passamonti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
Erin M. Bange et al.
NATURE MEDICINE (2021)
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
Nassim Kamar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
Evangelos Terpos et al.
BLOOD CANCER JOURNAL (2021)
Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine
Chiara Agrati et al.
MICROORGANISMS (2021)
Approaches and Challenges in SARS-CoV-2 Vaccine Development
Gabriel Dagotto et al.
CELL HOST & MICROBE (2020)
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
Francesco Passamonti et al.
LANCET HAEMATOLOGY (2020)
An mRNA Vaccine against SARS-CoV-2-Preliminary Report
L. A. Jackson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications
Divij Mathew et al.
SCIENCE (2020)
Risk factors and outcome of COVID-19 in patients with hematological malignancies
Jose Luis Pinana et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)
Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
Abi Vijenthira et al.
BLOOD (2020)
Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub
William A. Wood et al.
BLOOD ADVANCES (2020)
T cell responses in patients with COVID-19
Zeyu Chen et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Vaccination of patients with haematological malignancies who did not have transplantations: guidelines from the 2017 European Conference on Infections in Leukaemia (ECIL 7)
Malgorzata Mikulska et al.
LANCET INFECTIOUS DISEASES (2019)
Vaccination of haemopoietic stem cell transplant recipients: guidelines of the 2017 European Conference on Infections in Leukaemia (ECIL 7)
Catherine Cordonnier et al.
LANCET INFECTIOUS DISEASES (2019)
Infectious diseases and immunological markers associated with patients with non-Hodgkin lymphoma treated with rituximab
Kleber Jordao de Souza et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2018)
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Gilles Salles et al.
ADVANCES IN THERAPY (2017)
Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib
Clare Sun et al.
JAMA ONCOLOGY (2016)
Aetiology and resistance in bacteraemias among adult and paediatric haematology and cancer patients
Malgorzata Mikulska et al.
JOURNAL OF INFECTION (2014)
Lenalidomide-Induced Immunomodulation in Multiple Myeloma: Impact on Vaccines and Antitumor Responses
Kimberly Noonan et al.
CLINICAL CANCER RESEARCH (2012)
Long-term patterns of humoral and cellular response after vaccination against influenza A (H1N1) in patients with hematologic malignancies
Jacopo Mariotti et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2012)
Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment
Olav Erich Yri et al.
BLOOD (2011)
Impaired Response to Influenza Vaccine Associated with Persistent Memory B Cell Depletion in Non-Hodgkin's Lymphoma Patients Treated with Rituximab-Containing Regimens
Davide Bedognetti et al.
JOURNAL OF IMMUNOLOGY (2011)
High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication
F. Cabanillas et al.
ANNALS OF ONCOLOGY (2006)
Efficacy of the Influenza Vaccine in Patients with Malignant Lymphoma
Joseph J. Mazza et al.
CLINICAL MEDICINE & RESEARCH (2005)
分享论文
